Idera Presents Preclinical Data Demonstrating Enhanced Systemic Anti-Tumor Activity from Combination Treatment with Intra-tumoral ...
CAMBRIDGE, Mass. and EXTON, Pa., April 19, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today …